Autres langues FibroBiologics, Inc.

Actions

FBLG

US31573L2043

Recherche biotechnologique et médicale

Temps Différé Nasdaq 21:28:34 22/09/2026			Varia. 5j.	Varia. 1 janv.
1,340 ^USD	-1,47%		-6,94%	-70,21%

27/08	FibroBiologics, Inc. livre son troisième lot de CYWC628 pour l'essai clinique de phase 1/2 sur l'ulcère du pied diabétique	CI
24/08	FibroBiologics, Inc. annonce la nomination de Leigh Steinberg à son conseil d'administration	CI

Autres langues

15/09	FibroBiologics, Inc. announced that it has received $0.500001 million in funding
08/09	Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications
01/09	FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
27/08	FibroBiologics, Inc. Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
24/08	Fibrobiologics, Inc. Announces Appointment of Leigh Steinberg to Board of Directors
20/08	FibroBiologics : Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
20/08	FibroBiologics, Inc. Announces Acceptance of Australian Patent Application for Cannabidiol Adjuvant Therapy for Treatment of Degenerative Disc Disease
18/08	FibroBiologics : Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
18/08	FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints
12/08	FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
06/08	FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
31/07	FibroBiologics : Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
31/07	FibroBiologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
09/07	FibroBiologics, Inc. Announces Appointment of Kathleen 'Kate' Rubins to Board of Directors
09/07	FibroBiologics, Inc. Announces the Resignation of Matt Link from the Board of Directors, Effective July 2, 2026
07/07	FibroBiologics Completes Manufacturing Of Third Batch Of CYWC628 Drug Product For Phase 1/2 Diabetic Foot Ulcer Clinical Trial
07/07	FibroBiologics : Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
30/06	FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
29/06	FibroBiologics Closes Private Placement
29/06	FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
29/06	FibroBiologics, Inc. announced that it has received $3 million in funding
26/06	FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
25/06	FibroBiologics, Inc. announced that it expects to receive $3 million in funding
23/06	Fibrobiologics, Inc. Announces Non Standing for Re-Election of Stacy Coen to the Board
22/06	FibroBiologics Says US Patent for Therapeutic Use of Fibroblasts in Wound Healing Receives Notice of Allowance